Oslo, Norway, 12 August 2025. EXACT Therapeutics (Euronext Growth: EXTX), a
clinical-stage precision medicine company, is pleased to announce that clinical
data from its ACTIVATE Phase 1 trial in patients with liver metastases of
colorectal origin  (NCT04021277) will be presented at the upcoming European
Society for Medical Oncology (ESMO) Congress 2025, taking place 17-21 October,
2025 in Berlin, Germany.  

Details of the poster presentation are as follows: 

Poster #: 4176 

Title: First-in-Human Study of Acoustic Cluster Therapy consisting of PS101
combined with Chemotherapy and insonation in Patients with Liver Metastases of
Colorectal Cancer Origin  

The e-poster will be available on the Company's website on 18 October, 2025. 


About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound and microbubbles to enable targeted drug delivery in
oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be
applied to a wide range of therapeutic agents within oncology and across a
multitude of other indications, including brain diseases. EXACT Therapeutics'
shares are traded on Euronext Growth Oslo (EXTX). Further information may be
found here:        www.exact-tx.com    
 

For further information, please contact: 

Per Walday 
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com